APO Research
Talk to an analyst

APO RESEARCH · REPORT

IBS-C Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global IBS-C Drugs Market Outlook and Growth Opportunities 2026

20 December 2025212 pages

Choose your research edition.

Industry ResearchIBS-C Drugs Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal IBS-C Drugs Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal IBS-C Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IBS-C Drugs Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal IBS-C Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global IBS-C Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for IBS-C Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IBS-C Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IBS-C Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the IBS-C Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the IBS-C Drugs market include Abbott Laboratories, Actavis Nordic A/S, Albireo Pharma Inc, Ardelyx, Inc, Astellas Pharmaceuticals, Bama-Geve, SLU, Catalent Pharmaceuticals Solutions, Ferring BV and Ironwood Pharmaceuticals, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IBS-C Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IBS-C Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IBS-C Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IBS-C Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

IBS-C Drugs Segment by Company

Abbott Laboratories

Actavis Nordic A/S

Albireo Pharma Inc

Ardelyx, Inc

Astellas Pharmaceuticals

Bama-Geve, SLU

Catalent Pharmaceuticals Solutions

Ferring BV

Ironwood Pharmaceuticals, Inc

Norgine B.V

Novartis Pharma Ag

Ono Pharmaceutical Co., Ltd

Prometheus Laboratories Inc

Salix Pharmaceuticals Ltd

Sucampo Pharmaceuticals

Synergy Pharmaceuticals

Synthetic Biologics, Inc

Teva Pharmaceutical Industries

The Menarini Group

Yuhan Corp

Astrazeneca Plc

Nestle

IBS-C Drugs Segment by Type

Stimulant Laxatives

Linaclotide

Lubiprostone

Osmotic Laxatives

Others

IBS-C Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

IBS-C Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global IBS-C Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions IBS-C Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify IBS-C Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze IBS-C Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IBS-C Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IBS-C Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IBS-C Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IBS-C Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global IBS-C Drugs industry.

Chapter 3: Detailed analysis of IBS-C Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of IBS-C Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of IBS-C Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. IBS-C Drugs Industry Trends Table 2. IBS-C Drugs Industry Drivers Table 3. IBS-C Drugs Industry Opportunities and Challenges Table 4. IBS-C Drugs Industry Restraints Table 5. Global IBS-C Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global IBS-C Drugs Revenue Share by Company (2021-2026) Table 7. Global IBS-C Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global IBS-C Drugs Sales Volume Share by Company (2021-2026) Table 9. Global IBS-C Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global IBS-C Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global IBS-C Drugs Key Company Manufacturing Base & Headquarters Table 12. Global IBS-C Drugs Company, Product Type & Application Table 13. Global IBS-C Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global IBS-C Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Stimulant Laxatives Table 18. Significant Companies of Linaclotide Table 19. Significant Companies of Lubiprostone Table 20. Significant Companies of Osmotic Laxatives Table 21. Significant Companies of Others Table 22. Global IBS-C Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global IBS-C Drugs Sales Volume by Type (2021-2026) & (K Units) Table 24. Global IBS-C Drugs Sales Volume by Type (2027-2032) & (K Units) Table 25. Global IBS-C Drugs Sales Volume Share by Type (2021-2026) Table 26. Global IBS-C Drugs Sales Volume Share by Type (2027-2032) Table 27. Global IBS-C Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global IBS-C Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global IBS-C Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global IBS-C Drugs Sales Value Share by Type (2021-2026) Table 31. Global IBS-C Drugs Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Pharmacies Table 33. Significant Companies of Online Pharmacies Table 34. Significant Companies of Retail Pharmacies Table 35. Global IBS-C Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global IBS-C Drugs Sales Volume by Application (2021-2026) & (K Units) Table 37. Global IBS-C Drugs Sales Volume by Application (2027-2032) & (K Units) Table 38. Global IBS-C Drugs Sales Volume Share by Application (2021-2026) Table 39. Global IBS-C Drugs Sales Volume Share by Application (2027-2032) Table 40. Global IBS-C Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global IBS-C Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global IBS-C Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global IBS-C Drugs Sales Value Share by Application (2021-2026) Table 44. Global IBS-C Drugs Sales Value Share by Application (2027-2032) Table 45. Global IBS-C Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global IBS-C Drugs Sales by Region (2021-2026) & (K Units) Table 47. Global IBS-C Drugs Sales Market Share by Region (2021-2026) Table 48. Global IBS-C Drugs Sales by Region (2027-2032) & (K Units) Table 49. Global IBS-C Drugs Sales Market Share by Region (2027-2032) Table 50. Global IBS-C Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global IBS-C Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global IBS-C Drugs Sales Value Share by Region (2021-2026) Table 53. Global IBS-C Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global IBS-C Drugs Sales Value Share by Region (2027-2032) Table 55. Global IBS-C Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global IBS-C Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global IBS-C Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global IBS-C Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 60. Global IBS-C Drugs Sales Market Share by Country (2021-2026) Table 61. Global IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 62. Global IBS-C Drugs Sales Market Share by Country (2027-2032) Table 63. Global IBS-C Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global IBS-C Drugs Sales Value Market Share by Country (2021-2026) Table 65. Global IBS-C Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global IBS-C Drugs Sales Value Market Share by Country (2027-2032) Table 67. Abbott Laboratories Company Information Table 68. Abbott Laboratories Business Overview Table 69. Abbott Laboratories IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Abbott Laboratories IBS-C Drugs Product Portfolio Table 71. Abbott Laboratories Recent Development Table 72. Actavis Nordic A/S Company Information Table 73. Actavis Nordic A/S Business Overview Table 74. Actavis Nordic A/S IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Actavis Nordic A/S IBS-C Drugs Product Portfolio Table 76. Actavis Nordic A/S Recent Development Table 77. Albireo Pharma Inc Company Information Table 78. Albireo Pharma Inc Business Overview Table 79. Albireo Pharma Inc IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Albireo Pharma Inc IBS-C Drugs Product Portfolio Table 81. Albireo Pharma Inc Recent Development Table 82. Ardelyx, Inc Company Information Table 83. Ardelyx, Inc Business Overview Table 84. Ardelyx, Inc IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Ardelyx, Inc IBS-C Drugs Product Portfolio Table 86. Ardelyx, Inc Recent Development Table 87. Astellas Pharmaceuticals Company Information Table 88. Astellas Pharmaceuticals Business Overview Table 89. Astellas Pharmaceuticals IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Astellas Pharmaceuticals IBS-C Drugs Product Portfolio Table 91. Astellas Pharmaceuticals Recent Development Table 92. Bama-Geve, SLU Company Information Table 93. Bama-Geve, SLU Business Overview Table 94. Bama-Geve, SLU IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Bama-Geve, SLU IBS-C Drugs Product Portfolio Table 96. Bama-Geve, SLU Recent Development Table 97. Catalent Pharmaceuticals Solutions Company Information Table 98. Catalent Pharmaceuticals Solutions Business Overview Table 99. Catalent Pharmaceuticals Solutions IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio Table 101. Catalent Pharmaceuticals Solutions Recent Development Table 102. Ferring BV Company Information Table 103. Ferring BV Business Overview Table 104. Ferring BV IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Ferring BV IBS-C Drugs Product Portfolio Table 106. Ferring BV Recent Development Table 107. Ironwood Pharmaceuticals, Inc Company Information Table 108. Ironwood Pharmaceuticals, Inc Business Overview Table 109. Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio Table 111. Ironwood Pharmaceuticals, Inc Recent Development Table 112. Norgine B.V Company Information Table 113. Norgine B.V Business Overview Table 114. Norgine B.V IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Norgine B.V IBS-C Drugs Product Portfolio Table 116. Norgine B.V Recent Development Table 117. Novartis Pharma Ag Company Information Table 118. Novartis Pharma Ag Business Overview Table 119. Novartis Pharma Ag IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Novartis Pharma Ag IBS-C Drugs Product Portfolio Table 121. Novartis Pharma Ag Recent Development Table 122. Ono Pharmaceutical Co., Ltd Company Information Table 123. Ono Pharmaceutical Co., Ltd Business Overview Table 124. Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio Table 126. Ono Pharmaceutical Co., Ltd Recent Development Table 127. Prometheus Laboratories Inc Company Information Table 128. Prometheus Laboratories Inc Business Overview Table 129. Prometheus Laboratories Inc IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Prometheus Laboratories Inc IBS-C Drugs Product Portfolio Table 131. Prometheus Laboratories Inc Recent Development Table 132. Salix Pharmaceuticals Ltd Company Information Table 133. Salix Pharmaceuticals Ltd Business Overview Table 134. Salix Pharmaceuticals Ltd IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio Table 136. Salix Pharmaceuticals Ltd Recent Development Table 137. Sucampo Pharmaceuticals Company Information Table 138. Sucampo Pharmaceuticals Business Overview Table 139. Sucampo Pharmaceuticals IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio Table 141. Sucampo Pharmaceuticals Recent Development Table 142. Synergy Pharmaceuticals Company Information Table 143. Synergy Pharmaceuticals Business Overview Table 144. Synergy Pharmaceuticals IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Synergy Pharmaceuticals IBS-C Drugs Product Portfolio Table 146. Synergy Pharmaceuticals Recent Development Table 147. Synthetic Biologics, Inc Company Information Table 148. Synthetic Biologics, Inc Business Overview Table 149. Synthetic Biologics, Inc IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Synthetic Biologics, Inc IBS-C Drugs Product Portfolio Table 151. Synthetic Biologics, Inc Recent Development Table 152. Teva Pharmaceutical Industries Company Information Table 153. Teva Pharmaceutical Industries Business Overview Table 154. Teva Pharmaceutical Industries IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio Table 156. Teva Pharmaceutical Industries Recent Development Table 157. The Menarini Group Company Information Table 158. The Menarini Group Business Overview Table 159. The Menarini Group IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. The Menarini Group IBS-C Drugs Product Portfolio Table 161. The Menarini Group Recent Development Table 162. Yuhan Corp Company Information Table 163. Yuhan Corp Business Overview Table 164. Yuhan Corp IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Yuhan Corp IBS-C Drugs Product Portfolio Table 166. Yuhan Corp Recent Development Table 167. Astrazeneca Plc Company Information Table 168. Astrazeneca Plc Business Overview Table 169. Astrazeneca Plc IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Astrazeneca Plc IBS-C Drugs Product Portfolio Table 171. Astrazeneca Plc Recent Development Table 172. Nestle Company Information Table 173. Nestle Business Overview Table 174. Nestle IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. Nestle IBS-C Drugs Product Portfolio Table 176. Nestle Recent Development Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. IBS-C Drugs Distributors List Table 180. IBS-C Drugs Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. IBS-C Drugs Product Image Figure 2. Global IBS-C Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IBS-C Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global IBS-C Drugs Sales (2021-2032) & (K Units) Figure 5. Global IBS-C Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global IBS-C Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Stimulant Laxatives Image Figure 10. Linaclotide Image Figure 11. Lubiprostone Image Figure 12. Osmotic Laxatives Image Figure 13. Others Image Figure 14. Global IBS-C Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global IBS-C Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global IBS-C Drugs Sales Volume Share by Type (2021-2032) Figure 17. Global IBS-C Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global IBS-C Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global IBS-C Drugs Sales Value Share by Type (2021-2032) Figure 20. Hospital Pharmacies Image Figure 21. Online Pharmacies Image Figure 22. Retail Pharmacies Image Figure 23. Global IBS-C Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global IBS-C Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global IBS-C Drugs Sales Volume Share by Application (2021-2032) Figure 26. Global IBS-C Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global IBS-C Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global IBS-C Drugs Sales Value Share by Application (2021-2032) Figure 29. Global IBS-C Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global IBS-C Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global IBS-C Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global IBS-C Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America IBS-C Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. North America IBS-C Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe IBS-C Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Europe IBS-C Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific IBS-C Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific IBS-C Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America IBS-C Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. South America IBS-C Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa IBS-C Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa IBS-C Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt IBS-C Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt IBS-C Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt IBS-C Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. IBS-C Drugs Value Chain Figure 128. Manufacturing Cost Structure Figure 129. IBS-C Drugs Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Stimulant Laxatives
  • Linaclotide
  • Lubiprostone
  • Osmotic Laxatives
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Abbott Laboratories
  • Actavis Nordic A/S
  • Albireo Pharma Inc
  • Ardelyx, Inc
  • Astellas Pharmaceuticals
  • Bama-Geve, SLU
  • Catalent Pharmaceuticals Solutions
  • Ferring BV
  • Ironwood Pharmaceuticals, Inc
  • Norgine B.V
  • Novartis Pharma Ag
  • Ono Pharmaceutical Co., Ltd
  • Prometheus Laboratories Inc
  • Salix Pharmaceuticals Ltd
  • Sucampo Pharmaceuticals
  • Synergy Pharmaceuticals
  • Synthetic Biologics, Inc
  • Teva Pharmaceutical Industries
  • The Menarini Group
  • Yuhan Corp
  • Astrazeneca Plc
  • Nestle

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global IBS-C Drugs Sales Value (2021-2032)
  4. 1.2.2 Global IBS-C Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global IBS-C Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 IBS-C Drugs Market Dynamics
  1. 2.1 IBS-C Drugs Industry Trends
  2. 2.2 IBS-C Drugs Industry Drivers
  3. 2.3 IBS-C Drugs Industry Opportunities and Challenges
  4. 2.4 IBS-C Drugs Industry Restraints
3 IBS-C Drugs Market by Company
  1. 3.1 Global IBS-C Drugs Company Revenue Ranking in 2025
  2. 3.2 Global IBS-C Drugs Revenue by Company (2021-2026)
  3. 3.3 Global IBS-C Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global IBS-C Drugs Average Price by Company (2021-2026)
  5. 3.5 Global IBS-C Drugs Company Ranking (2024-2026)
  6. 3.6 Global IBS-C Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global IBS-C Drugs Company Product Type and Application
  8. 3.8 Global IBS-C Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global IBS-C Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 IBS-C Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 IBS-C Drugs Market by Type
  1. 4.1 IBS-C Drugs Type Introduction
  2. 4.1.1 Stimulant Laxatives
  3. 4.1.2 Linaclotide
  4. 4.1.3 Lubiprostone
  5. 4.1.4 Osmotic Laxatives
  6. 4.1.5 Others
  7. 4.2 Global IBS-C Drugs Sales Volume by Type
  8. 4.2.1 Global IBS-C Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global IBS-C Drugs Sales Volume by Type (2021-2032)
  10. 4.2.3 Global IBS-C Drugs Sales Volume Share by Type (2021-2032)
  11. 4.3 Global IBS-C Drugs Sales Value by Type
  12. 4.3.1 Global IBS-C Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global IBS-C Drugs Sales Value by Type (2021-2032)
  14. 4.3.3 Global IBS-C Drugs Sales Value Share by Type (2021-2032)
5 IBS-C Drugs Market by Application
  1. 5.1 IBS-C Drugs Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global IBS-C Drugs Sales Volume by Application
  6. 5.2.1 Global IBS-C Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IBS-C Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global IBS-C Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global IBS-C Drugs Sales Value by Application
  10. 5.3.1 Global IBS-C Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global IBS-C Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global IBS-C Drugs Sales Value Share by Application (2021-2032)
6 IBS-C Drugs Regional Sales and Value Analysis
  1. 6.1 Global IBS-C Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IBS-C Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global IBS-C Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global IBS-C Drugs Sales by Region (2027-2032)
  5. 6.3 Global IBS-C Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global IBS-C Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global IBS-C Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global IBS-C Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global IBS-C Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America IBS-C Drugs Sales Value (2021-2032)
  12. 6.6.2 North America IBS-C Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe IBS-C Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe IBS-C Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific IBS-C Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific IBS-C Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America IBS-C Drugs Sales Value (2021-2032)
  21. 6.9.2 South America IBS-C Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa IBS-C Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa IBS-C Drugs Sales Value Share by Country, 2025 VS 2032
7 IBS-C Drugs Country-level Sales and Value Analysis
  1. 7.1 Global IBS-C Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global IBS-C Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global IBS-C Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global IBS-C Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global IBS-C Drugs Sales by Country (2027-2032)
  6. 7.4 Global IBS-C Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global IBS-C Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global IBS-C Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA IBS-C Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada IBS-C Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico IBS-C Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany IBS-C Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France IBS-C Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. IBS-C Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy IBS-C Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain IBS-C Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia IBS-C Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands IBS-C Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries IBS-C Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China IBS-C Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan IBS-C Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea IBS-C Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India IBS-C Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia IBS-C Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia IBS-C Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil IBS-C Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina IBS-C Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile IBS-C Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia IBS-C Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru IBS-C Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia IBS-C Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel IBS-C Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE IBS-C Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey IBS-C Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran IBS-C Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt IBS-C Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt IBS-C Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt IBS-C Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott Laboratories
  2. 8.1.1 Abbott Laboratories Company Information
  3. 8.1.2 Abbott Laboratories Business Overview
  4. 8.1.3 Abbott Laboratories IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Laboratories IBS-C Drugs Product Portfolio
  6. 8.1.5 Abbott Laboratories Recent Developments
  7. 8.2 Actavis Nordic A/S
  8. 8.2.1 Actavis Nordic A/S Company Information
  9. 8.2.2 Actavis Nordic A/S Business Overview
  10. 8.2.3 Actavis Nordic A/S IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Actavis Nordic A/S IBS-C Drugs Product Portfolio
  12. 8.2.5 Actavis Nordic A/S Recent Developments
  13. 8.3 Albireo Pharma Inc
  14. 8.3.1 Albireo Pharma Inc Company Information
  15. 8.3.2 Albireo Pharma Inc Business Overview
  16. 8.3.3 Albireo Pharma Inc IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Albireo Pharma Inc IBS-C Drugs Product Portfolio
  18. 8.3.5 Albireo Pharma Inc Recent Developments
  19. 8.4 Ardelyx, Inc
  20. 8.4.1 Ardelyx, Inc Company Information
  21. 8.4.2 Ardelyx, Inc Business Overview
  22. 8.4.3 Ardelyx, Inc IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Ardelyx, Inc IBS-C Drugs Product Portfolio
  24. 8.4.5 Ardelyx, Inc Recent Developments
  25. 8.5 Astellas Pharmaceuticals
  26. 8.5.1 Astellas Pharmaceuticals Company Information
  27. 8.5.2 Astellas Pharmaceuticals Business Overview
  28. 8.5.3 Astellas Pharmaceuticals IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Astellas Pharmaceuticals IBS-C Drugs Product Portfolio
  30. 8.5.5 Astellas Pharmaceuticals Recent Developments
  31. 8.6 Bama-Geve, SLU
  32. 8.6.1 Bama-Geve, SLU Company Information
  33. 8.6.2 Bama-Geve, SLU Business Overview
  34. 8.6.3 Bama-Geve, SLU IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bama-Geve, SLU IBS-C Drugs Product Portfolio
  36. 8.6.5 Bama-Geve, SLU Recent Developments
  37. 8.7 Catalent Pharmaceuticals Solutions
  38. 8.7.1 Catalent Pharmaceuticals Solutions Company Information
  39. 8.7.2 Catalent Pharmaceuticals Solutions Business Overview
  40. 8.7.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio
  42. 8.7.5 Catalent Pharmaceuticals Solutions Recent Developments
  43. 8.8 Ferring BV
  44. 8.8.1 Ferring BV Company Information
  45. 8.8.2 Ferring BV Business Overview
  46. 8.8.3 Ferring BV IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Ferring BV IBS-C Drugs Product Portfolio
  48. 8.8.5 Ferring BV Recent Developments
  49. 8.9 Ironwood Pharmaceuticals, Inc
  50. 8.9.1 Ironwood Pharmaceuticals, Inc Company Information
  51. 8.9.2 Ironwood Pharmaceuticals, Inc Business Overview
  52. 8.9.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio
  54. 8.9.5 Ironwood Pharmaceuticals, Inc Recent Developments
  55. 8.10 Norgine B.V
  56. 8.10.1 Norgine B.V Company Information
  57. 8.10.2 Norgine B.V Business Overview
  58. 8.10.3 Norgine B.V IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Norgine B.V IBS-C Drugs Product Portfolio
  60. 8.10.5 Norgine B.V Recent Developments
  61. 8.11 Novartis Pharma Ag
  62. 8.11.1 Novartis Pharma Ag Company Information
  63. 8.11.2 Novartis Pharma Ag Business Overview
  64. 8.11.3 Novartis Pharma Ag IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Novartis Pharma Ag IBS-C Drugs Product Portfolio
  66. 8.11.5 Novartis Pharma Ag Recent Developments
  67. 8.12 Ono Pharmaceutical Co., Ltd
  68. 8.12.1 Ono Pharmaceutical Co., Ltd Company Information
  69. 8.12.2 Ono Pharmaceutical Co., Ltd Business Overview
  70. 8.12.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio
  72. 8.12.5 Ono Pharmaceutical Co., Ltd Recent Developments
  73. 8.13 Prometheus Laboratories Inc
  74. 8.13.1 Prometheus Laboratories Inc Company Information
  75. 8.13.2 Prometheus Laboratories Inc Business Overview
  76. 8.13.3 Prometheus Laboratories Inc IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Prometheus Laboratories Inc IBS-C Drugs Product Portfolio
  78. 8.13.5 Prometheus Laboratories Inc Recent Developments
  79. 8.14 Salix Pharmaceuticals Ltd
  80. 8.14.1 Salix Pharmaceuticals Ltd Company Information
  81. 8.14.2 Salix Pharmaceuticals Ltd Business Overview
  82. 8.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio
  84. 8.14.5 Salix Pharmaceuticals Ltd Recent Developments
  85. 8.15 Sucampo Pharmaceuticals
  86. 8.15.1 Sucampo Pharmaceuticals Company Information
  87. 8.15.2 Sucampo Pharmaceuticals Business Overview
  88. 8.15.3 Sucampo Pharmaceuticals IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio
  90. 8.15.5 Sucampo Pharmaceuticals Recent Developments
  91. 8.16 Synergy Pharmaceuticals
  92. 8.16.1 Synergy Pharmaceuticals Company Information
  93. 8.16.2 Synergy Pharmaceuticals Business Overview
  94. 8.16.3 Synergy Pharmaceuticals IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Synergy Pharmaceuticals IBS-C Drugs Product Portfolio
  96. 8.16.5 Synergy Pharmaceuticals Recent Developments
  97. 8.17 Synthetic Biologics, Inc
  98. 8.17.1 Synthetic Biologics, Inc Company Information
  99. 8.17.2 Synthetic Biologics, Inc Business Overview
  100. 8.17.3 Synthetic Biologics, Inc IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Synthetic Biologics, Inc IBS-C Drugs Product Portfolio
  102. 8.17.5 Synthetic Biologics, Inc Recent Developments
  103. 8.18 Teva Pharmaceutical Industries
  104. 8.18.1 Teva Pharmaceutical Industries Company Information
  105. 8.18.2 Teva Pharmaceutical Industries Business Overview
  106. 8.18.3 Teva Pharmaceutical Industries IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio
  108. 8.18.5 Teva Pharmaceutical Industries Recent Developments
  109. 8.19 The Menarini Group
  110. 8.19.1 The Menarini Group Company Information
  111. 8.19.2 The Menarini Group Business Overview
  112. 8.19.3 The Menarini Group IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 The Menarini Group IBS-C Drugs Product Portfolio
  114. 8.19.5 The Menarini Group Recent Developments
  115. 8.20 Yuhan Corp
  116. 8.20.1 Yuhan Corp Company Information
  117. 8.20.2 Yuhan Corp Business Overview
  118. 8.20.3 Yuhan Corp IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Yuhan Corp IBS-C Drugs Product Portfolio
  120. 8.20.5 Yuhan Corp Recent Developments
  121. 8.21 Astrazeneca Plc
  122. 8.21.1 Astrazeneca Plc Company Information
  123. 8.21.2 Astrazeneca Plc Business Overview
  124. 8.21.3 Astrazeneca Plc IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Astrazeneca Plc IBS-C Drugs Product Portfolio
  126. 8.21.5 Astrazeneca Plc Recent Developments
  127. 8.22 Nestle
  128. 8.22.1 Nestle Company Information
  129. 8.22.2 Nestle Business Overview
  130. 8.22.3 Nestle IBS-C Drugs Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Nestle IBS-C Drugs Product Portfolio
  132. 8.22.5 Nestle Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IBS-C Drugs Value Chain Analysis
  2. 9.1.1 IBS-C Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IBS-C Drugs Sales Mode & Process
  6. 9.2 IBS-C Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IBS-C Drugs Distributors
  9. 9.2.3 IBS-C Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst